1. Generics Bulletin
  2. >>Products

Amneal’s Shares Slump On Slashed Earnings Outlook and Cost-Cutting Plan

 
• By Aidan Fry

Investors have downgraded their valuation of Amneal after the US firm blamed a highly competitive local generics market for slashing its earnings forecast. To improve its competitiveness, Amneal is planning to cut 550 jobs and close two plants.  

Cutting The Costs/ Inflation Comes Back - Image
Amneal is looking to cut operating costs as if faces intense competition in the US generics arena • Source: Shutterstock

Amneal’s share price slumped by more than a third on 10 July after the company slashed its earnings forecast and unveiled the outline of a broad-ranging restructuring plan aimed at cutting around $50m per year from the group’s cost base. This will include 550 job losses and closure of two US facilities.

Whereas shares had been trading above $14 as recently as early May, they had tumbled to $4

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival

 
• By Dean Rudge

Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.